← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PROTEIN KINASE INHIBITORS › Phosphatidylinositol-3-kinase (Pi3K) inhibitors
inavolisib
L01EM06
Adult Dosing
- 9 mg orally once daily, taken with food
- Administered in combination with palbociclib and fulvestrant
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
Indications
- Treatment of PIK3CA-mutated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in combination with palbociclib and fulvestrant after disease progression on endocrine-based therapy
Mechanism of Action
- Potent and selective inhibitor of PI3K alpha (phosphatidylinositol 3-kinase alpha), inducing degradation of mutant p110alpha protein
Contraindications
- Severe hypersensitivity to inavolisib or any of its excipients
Adverse Reactions
- Hyperglycemia
- Stomatitis
- Diarrhea
- Neutropenia
- Fatigue
- Thrombocytopenia
- Decreased appetite
- Rash
- Nausea
- Anemia
Drug Interactions
- Avoid concurrent use with strong or moderate CYP3A4 inducers
- Avoid concurrent use with strong or moderate CYP3A4 inhibitors
- Avoid concurrent use with strong or moderate P-gp inhibitors if they cannot be avoided
- Use caution with acid-reducing agents if solubility is pH-dependent
Curated Content: Needs Vetting Before Put to Clinical Use